Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou(Fudan University), Hui‐Chuan Sun(Fudan University), Zheng Wang(Central South University), Wen‐Ming Cong(Second Military Medical University), Jianhua Wang(Fudan University), Mengsu Zeng(Sun Yat-sen University), Weiping Zhou(Second Military Medical University), Ping Bie(Army Medical University), Lianxin Liu(Harbin Medical University), Tianfu Wen(Sichuan University), Guohong Han(Xijing Hospital), Maoqiang Wang(Chinese PLA General Hospital), Ruibao Liu(Harbin Medical University), Ligong Lu(Guangdong General Hospital), Zhengang Ren(Fudan University), Minshan Chen(Sun Yat-sen University), Zhao‐Chong Zeng(Sun Yat-sen University), Ping Liang(Chinese PLA General Hospital), Changhong Liang(Guangdong General Hospital), Min Chen(Sun Yat-sen University), Fuhua Yan(Ruijin Hospital), Wen‐Ping Wang(Sichuan University), Yuan Ji(Sun Yat-sen University), Jing‐Ping Yun(Sun Yat-sen University), Dingfang Cai(Fudan University), Yongjun Chen(Shanghai Jiao Tong University), Wenwu Cheng(Fudan University Shanghai Cancer Center), Shuqun Cheng(Second Military Medical University), Chaoliu Dai(China Medical University), Wenzhi Guo(First Affiliated Hospital of Zhengzhou University), Baojin Hua(Beijing University of Chinese Medicine), Xiaowu Huang(Fudan University), Weidong Jia(Anhui Medical University), Yaming Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Ye‐Xiong Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Liang(Peking University), Tianshu Liu(Sun Yat-sen University), Guoyue Lv(Jilin University), Yilei Mao(Chinese Academy of Medical Sciences & Peking Union Medical College), Tao Peng(Guangxi Medical University), Weixin Ren(Xinjiang Medical University), Hongcheng Shi(Sun Yat-sen University), Guo‐Ming Shi(Fudan University), Kaishan Tao(Xijing Hospital), Wentao Wang(Sichuan University), Xiaoying Wang(Fudan University), Zhiming Wang(Central South University), Bang‐De Xiang(Tumor Hospital of Guangxi Medical University), Baocai Xing(Peking University), Jianming Xu(Academy of Military Medical Sciences), Jiamei Yang(Sun Yat-sen University), Jianyong Yang(Sun Yat-sen University), Yefa Yang(Second Military Medical University), Yunke Yang(Second Military Medical University), Sheng‐Long Ye(Fudan University), Zhengyu Yin(Zhongshan Hospital of Xiamen University), Bixiang Zhang(Fudan University), Boheng Zhang(Fudan University), Leida Zhang(Army Medical University), Shuijun Zhang(First Affiliated Hospital of Zhengzhou University), Ti Zhang(Tianjin Medical University Cancer Institute and Hospital), Yongfu Zhao(First Affiliated Hospital of Zhengzhou University), Honggang Zheng(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiye Zhu(Peking University), Kangshun Zhu(Second Affiliated Hospital of Guangzhou Medical University), Rong Liu(Harbin Medical University), Ying–Hong Shi(Fudan University), Yong‐Sheng Xiao(Fudan University), Zhi Dai(Fudan University), Gao‐Jun Teng(Zhongda Hospital Southeast University), Jianqiang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Weilin Wang(Sichuan University), Xiujun Cai(Sir Run Run Shaw Hospital), Qiang Li(Tianjin Medical University Cancer Institute and Hospital), Feng Shen(Second Military Medical University), Shukui Qin(81th Hospital of PLA), Jiahong Dong(Beijing Tsinghua Chang Gung Hospital), Jia Fan(Fudan University)
Liver Cancer
January 1, 2020
10.1159/000509424
Cited by 831Open Access
Full Text

Abstract

<b><i>Background:</i></b> Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. <b><i>Summary:</i></b> Since the publication of <i>Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition)</i> in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition <i>(2019 Edition)</i> was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. <b><i>Key Messages:</i></b> Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.

Related Papers

No related papers found

Powered by citation graph analysis